Thomas Balland

Develops and markets implants for the treatment of spinal disorders

Operates as a pharmaceutical company that develops and commercializes therapies for the treatment of ophthalmic diseases

Manufactures tracking devices for automotive industry

IPSA is an active manager focused on science-based companies within the European Union. They invest internationally in the ICT, life sciences, natural resources and energy sectors, particularly in France, the UK, Germany, the Netherlands and Denmark. They target high-growth businesses with innovative technology and an experienced management team with a proven track record of growth. They seek board representation, actively participate in strategic decisions, and aim to build their portfolio companies into market leaders. The firm prefers to be the lead or co-lead investor and invests between EUR 1-5 million per round, participating in successive financing rounds. They invest across development stages from startups to pre-IPO companies, and accompany their portfolio companies throughout their development. They favor companies with disruptive products or technology which have reached an advanced stage of development, are likely to generate significant revenues within two to three years, and have exit visibility through IPO or trade sale. In the life sciences sector, IPSA focuses on clinical-stage drug development, medical devices, drug delivery and development services. Their ICT investments are in domains including content, software, enabling technology and infrastructure. The firm also invests in the energy and natural resources sector, focusing on exploration and production, as well as on renewable energy and clean technology.

Operates as a global contract process development and manufacturer of biopharmaceuticals

Develops and supplies software

Functions as a College/University

Functions as a College/University

Develops and produces PC and console video games